## Antidepressant Use and Risk of Out-of-Hospital Cardiac Case–Time–Control Study

Clinical Pharmacology and Therapeutics 92, 72-79

DOI: 10.1038/clpt.2011.368

Citation Report

#	Article	IF	CITATIONS
1	Norepinephrine transporter function and human cardiovascular disease. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H1273-H1282.	1.5	76
2	Antidepressant use associated with increased cardiac arrest risk. Reactions Weekly, 2012, &NA, 4.	0.0	О
3	QTc Prolongation, Torsades de Pointes, and Psychotropic Medications. Psychosomatics, 2013, 54, 1-13.	2.5	269
4	The cardiovascular safety profile of escitalopram. European Neuropsychopharmacology, 2013, 23, 1391-1400.	0.3	43
5	Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. European Heart Journal, 2013, 34, 1506-1516.	1.0	47
6	TREATMENT OF DEPRESSION IN CARDIOVASCULAR DISEASE. Depression and Anxiety, 2013, 30, 328-341.	2.0	65
7	A Comparison of the Risk of QT Prolongation Among SSRIs. Annals of Pharmacotherapy, 2013, 47, 1330-1341.	0.9	115
8	A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Therapeutic Advances in Psychopharmacology, 2013, 3, 151-161.	1.2	25
9	Is Depression the Wrong Treatment Target for Improving Outcome in Coronary Artery Disease?. Psychotherapy and Psychosomatics, 2013, 82, 285-291.	4.0	27
10	Selective serotonin reuptake inhibitors and <i>torsade de pointes</i> : new concepts and new directions derived from a systematic review of case reports. Therapeutic Advances in Drug Safety, 2013, 4, 189-198.	1.0	29
11	Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events. Pharmacoepidemiology and Drug Safety, 2013, 22, 607-614.	0.9	12
12	SSRIs: A Premature Burial. Clinical Pharmacology and Therapeutics, 2013, 93, 234-235.	2.3	O
13	Response to "SSRIs: A Premature Burial― Clinical Pharmacology and Therapeutics, 2013, 93, 235-235.	2.3	0
14	Searching the Cytochrome P450 Enzymes for the Metabolism of Meranzin Hydrate: A Prospective Antidepressant Originating from Chaihu-Shugan-San. PLoS ONE, 2014, 9, e113819.	1.1	14
15	Antidepressant Drugs. Side Effects of Drugs Annual, 2014, 36, 11-25.	0.6	0
16	Major depression and first-time hospitalization with ischemic heart disease, cardiac procedures and mortality in the general population: A retrospective Danish population-based cohort study. European Journal of Preventive Cardiology, 2014, 21, 532-540.	0.8	30
17	On the Validity of the Case-Time-Control Design for Autocorrelated Exposure Histories. Epidemiology, 2014, 25, 110-113.	1.2	15
18	Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram. Expert Opinion on Drug Safety, 2014, 13, 197-205.	1.0	10

#	Article	IF	Citations
19	Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European Heart Journal, 2014, 35, 1306-1315.	1.0	103
20	Antipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest. Clinical Pharmacology and Therapeutics, 2014, 96, 490-497.	2.3	31
21	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. European Journal of Internal Medicine, 2014, 25, 617-623.	1.0	75
22	Risk Factors for Sudden Cardiac Death Among Patients with Alcohol Dependence: A Nested Case–Control Study. Alcoholism: Clinical and Experimental Research, 2015, 39, 1797-1804.	1.4	4
24	Cognitive Function, Quality of Life and Mental Health in Survivors of Out-of-Hospital Cardiac Arrest: A Review. Anaesthesia and Intensive Care, 2015, 43, 568-576.	0.2	78
25	The Spectrum of Epidemiology Underlying Sudden Cardiac Death. Circulation Research, 2015, 116, 1887-1906.	2.0	474
27	Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 883-892.	1.5	59
28	White Matter Hyperintensity Accumulation During Treatment of Late-Life Depression. Neuropsychopharmacology, 2015, 40, 3027-3035.	2.8	39
29	QT dynamics during treatment with sertindole. Therapeutic Advances in Psychopharmacology, 2015, 5, 26-31.	1.2	6
31	Quantification of Meranzin Hydrate in Rat Hippocampus and Plasma by LC–MS/MS: A Compound Derived from Chaihu–Shugan–San Displays Antidepressant Potential. Chromatographia, 2015, 78, 221-229.	0.7	1
32	Risk factors for QT prolongation associated with acute psychotropic drug overdose. American Journal of Emergency Medicine, 2015, 33, 142-149.	0.7	22
33	Management of Depression After Myocardial Infarction. Current Cardiology Reports, 2015, 17, 80.	1.3	16
34	A Pharmacovigilance Approach for Post-Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis. PLoS ONE, 2016, 11, e0154425.	1.1	24
35	Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study. PLoS ONE, 2016, 11, e0160768.	1.1	22
36	Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time—control study. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, pvw041.	1.4	63
37	Quantification of 16 QT-prolonging Drugs and Metabolites in Human Postmortem Blood and Cardiac Tissue Using UPLC–MS-MS. Journal of Analytical Toxicology, 2016, 40, 286-293.	1.7	7
38	Serotonin and norepinephrine reuptake inhibitors antidepressant use is related to lower baroreflex sensitivity independently of the severity of depressive symptoms. A community-study of 9213 participants from the Paris Prospective Study III. Atherosclerosis, 2016, 251, 55-62.	0.4	3
39	Association between major depression and cardiovascular risk: the role of antidepressant medication. Psychopharmacology, 2016, 233, 3289-3295.	1.5	12

#	Article	IF	CITATIONS
40	Genetic investigation of 100 heart genes in sudden unexplained death victims in a forensic setting. European Journal of Human Genetics, 2016, 24, 1797-1802.	1.4	65
41	Is the Chinese medicinal formula Guipi Decoction (å½'è,,¾æ±Þeffective as an adjunctive treatment for depression? A meta-analysis of randomized controlled trials. Chinese Journal of Integrative Medicine, 2017, 23, 386-395.	0.7	14
42	Sudden Cardiac Death. JACC: Clinical Electrophysiology, 2017, 3, 473-481.	1.3	13
43	Comparative Risk of Ventricular Arrhythmia and Sudden Cardiac Death Across Antidepressants in Patients With Depressive Disorders. Journal of Clinical Psychopharmacology, 2017, 37, 32-39.	0.7	12
44	A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology, 2017, 234, 3075-3081.	1.5	41
45	Life After Death: Surviving Cardiac Arrest—an Overview of Epidemiology, Best Acute Care Practices, and Considerations for Rehabilitation Care. Current Physical Medicine and Rehabilitation Reports, 2017, 5, 30-39.	0.3	5
46	Does macrolide use confer risk of out-of-hospital cardiac arrest compared with penicillin V? A Danish national case-crossover and case–time–control study. BMJ Open, 2018, 8, e019997.	0.8	1
47	Antidepressants and the risk of arrhythmia in elderly affected by a previous cardiovascular disease: a real-life investigation from Italy. European Journal of Clinical Pharmacology, 2018, 74, 119-129.	0.8	6
48	Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome. American Journal of Cardiology, 2018, 121, 182-187.	0.7	6
49	Citalopram and the KCNE1 D85N variant: a case report on the implications of a genetic modifier. European Heart Journal - Case Reports, 2018, 2, yty106.	0.3	2
50	Antidepressants-related cardiovascular adverse events using the adverse event reporting system. Psychiatry Research, 2018, 268, 441-446.	1.7	5
51	Distribution of Eight QT-Prolonging Drugs and Their Main Metabolites Between Postmortem Cardiac Tissue and Blood Reveals Potential Pitfalls in Toxicological Interpretation. Journal of Analytical Toxicology, 2018, 42, 375-383.	1.7	13
52	Cardiovascular Outcomes Associated With Clinical Use of Citalopram and Omeprazole: A Nationwide Populationâ€Based Cohort Study. Journal of the American Heart Association, 2019, 8, e011607.	1.6	9
53	Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study. Clinical Therapeutics, 2019, 41, 1128-1138.e8.	1.1	4
54	Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality. European Heart Journal, 2019, 40, 3110-3117.	1.0	28
55	Preadmission use of antidepressants and risk of complications and death after colorectal cancer surgery: a nationwide populationâ€based cohort study. Colorectal Disease, 2019, 21, 651-662.	0.7	1
56	Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531989138.	1.2	9
57	Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. European Heart Journal, 2020, 41, 1687-1696.	1.0	203

#	Article	IF	CITATIONS
58	Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 347-355.	1.4	21
59	Increased Odds of Ventricular Arrhythmias Associated with Selective Serotonin Reuptake Inhibitor Use among the Pediatric and Young Adult Population: A Case–Control Study. Journal of Pediatrics, 2020, 226, 173-178.e8.	0.9	0
60	Associations of anger, vital exhaustion, anti-depressant use, and poor social ties with incident atrial fibrillation: The Atherosclerosis Risk in Communities Study. European Journal of Preventive Cardiology, 2021, 28, 633-640.	0.8	22
61	Increased risk of fatal intoxication and polypharmacy among psychiatric patients at death. Journal of Forensic Sciences, 2021, 66, 255-264.	0.9	7
62	Severity of congenital long QT syndrome disease manifestation and risk of depression, anxiety, and mortality: a nationwide study. Europace, 2022, 24, 620-629.	0.7	7
63	Patient journey through cases of depression from claims database using machine learning algorithms. PLoS ONE, 2021, 16, e0247059.	1.1	2
64	Association of lithium use with rate of out-of-hospital cardiac arrest in patients with bipolar disorder. Journal of Affective Disorders Reports, 2021, 5, 100164.	0.9	1
65	5-HTT Deficiency in Male Mice Affects Healing and Behavior after Myocardial Infarction. Journal of Clinical Medicine, 2021, 10, 3104.	1.0	5
66	Outâ€ofâ€hospital cardiac arrest and differential risk of cardiac and nonâ€cardiac QTâ€prolonging drugs in 37 000 cases. British Journal of Clinical Pharmacology, 2022, 88, 820-829.	1.1	7
67	The role of QT-prolonging medications in a forensic autopsy study from Western Denmark. Forensic Science International, 2021, 325, 110889.	1.3	5
68	Psychische Störungen bei somatischen Krankheiten., 2015,, 1-114.		2
69	Mortality among People with Severe Mental Disorders Who Reach Old Age: A Longitudinal Study of a Community-Representative Sample of 37892 Men. PLoS ONE, 2014, 9, e111882.	1.1	67
70	Non-Hormonal Replacement Therapy Regimens: Do they have an Effect on Cardiovascular Risk?. Current Vascular Pharmacology, 2019, 17, 573-578.	0.8	1
71	SURVIVE: let the dead help the livingâ€"an autopsy-based cohort study for mapping risk markers of death among those with severe mental illnesses. Scandinavian Journal of Forensic Science, 2018, 24, 7-17.	1.0	16
72	Treatment of affective disorders in cardiac disease. Dialogues in Clinical Neuroscience, 2015, 17, 127-140.	1.8	18
73	Implementation of Warnings From Dear Doctor Letters (Rote-Hand-Briefe). Deutsches Ärzteblatt International, 2014, 111, 255-63.	0.6	23
74	QT Interval Prolongation after Cardiac Surgery; An Interesting Biological Phenomenon or A Clinical Problem? Data from the Prolonqit Study. , 2014, 04, .		2
75	Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of out-of-hospital cardiac arrest: real-world data from a population-based study. Europace, 2022, 24, 630-638.	0.7	2

#	ARTICLE	IF	Citations
76	Advances in discovering the interrelationship between mental disorders and heart diseases. Heart and Mind (Mumbai, India), 2017, 1, 71.	0.2	4
77	Psychische Störungen bei somatischen Krankheiten. , 2017, , 2693-2805.		6
79	Citalopram and QT prolongation. Vnitrni Lekarstvi, 2017, 63, 952-956.	0.1	2
80	Antidepressants and cardiovascular adverse events: A narrative review. ARYA Atherosclerosis, 2015, 11, 295-304.	0.4	37
81	Opioid use is associated with increased outâ€ofâ€hospital cardiac arrest risk among 40,000â€cases across two countries. British Journal of Clinical Pharmacology, 2021, , .	1.1	2
82	Exploring the use of psychotropic medication in cardiac patients with and without anxiety and its association with 1-year mortality. European Journal of Cardiovascular Nursing, 2022, 21, 612-619.	0.4	4
83	Risk of outâ€ofâ€hospital cardiac arrest in antidepressant drug users. British Journal of Clinical Pharmacology, 2022, 88, 3162-3171.	1.1	8
84	Fighting against sudden cardiac death: need for a paradigm shift—Adding near-term prevention and pre-emptive action to long-term prevention. European Heart Journal, 2022, 43, 1457-1464.	1.0	24
85	Evaluation of the Citalopram levels on QTc Interval in Rats using with Radio-telemetry. Osmangazİ Journal of Medicine, 0, 00, .	0.1	0
87	Drug-induced Sudden Death: A Scoping Review. Current Drug Safety, 2023, 18, 307-317.	0.3	2
88	Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A populationâ€based cohort study in older adults. Clinical and Translational Science, 2022, 15, 2105-2115.	1.5	6
89	Non-Cardiac Depolarization-Blocking Drugs Are Associated with Increased Risk of Out-of-Hospital Cardiac Arrest in the Community. , 2022, 1, 64-75.		2
90	Use of torsades de pointes risk drugs among patients with out-of-hospital cardiac arrest and likelihood of shockable rhythm and return of spontaneous circulation: A nationwide study. Resuscitation, 2022, 179, 105-113.	1.3	3
91	Depression: As a Risk Factor for Coronary Heart Disease. Research Journal of Pharmacology and Pharmacodynamics, 2022, , 139-145.	0.1	0
92	Cardiac Arrhythmias and Sudden Cardiac Death. , 2022, , 1149-1169.		0
93	QTc interval diurnal variations in patients treated with psychotropic medications: implications for the evaluation of drug induced QTc changes. International Review of Psychiatry, $0, 1-4$ .	1.4	1
94	Risk of cardiovascular events according to the tricyclic antidepressant dosage in patients with chronic pain: a retrospective cohort study. European Journal of Clinical Pharmacology, 2023, 79, 159-171.	0.8	2
95	KardiovaskulÃÆ Erkrankungen. , 2022, , 105-185.		0

# ARTICLE IF CITATIONS

96 Pharmacoepidemiology., 2022,, 1-55.